Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCraneware Regulatory News (CRW)

Share Price Information for Craneware (CRW)

Share Price is delayed by 15 minutes
Get Live Data
1,476.00    -14.00 (-0.94%)
Bid:
1,468.00
Ask:
1,476.00
Spread: 8.00 (0.545%)
Market Cap: £505.34m
CRW Live PriceLast checked at - London Stock Exchange

Intraday Craneware Share Chart

Share Buyback Programme

12 Apr 2023 07:00

RNS Number : 8866V
Craneware plc
12 April 2023
Β 

12 April 2023

Craneware plc

("Craneware" or the "Company" or the "Group")

Share buyback programme

The Board of Directors of Craneware ("Board") is pleased to announceΒ that it intends to commence a share buyback programme of Β£5 million ("Programme") from the date of this announcement. All shares acquired under the Programme will be held in treasury.

The Board firmly believes that the current market price does not reflect the substantial potential of the large addressable market opportunity of the Group, nor the significant operational progress it has made as it has successfully migrated to a cloud-based SaaS model. This migration further positions the Group to deliver on future growth and enhanced shareholder value. As a result, the Board believes that the buyback will provide an optimal use of cash to deliver value for shareholders by offsetting future dilution from existing share incentive schemes.

The Programme will operate under the authority granted to the Group by shareholders at the Group's most recent Annual General Meeting, held on 15 November 2022, and within the regulatory limit on the quantity of shares the Group may purchase on any single day. The Programme will be undertaken using a phased approach and have an initial duration of up to 3 calendar months.

The Board will keep the programme under review and will make a decision in due course on whether to extend it.

In order to implement the Programme, Craneware has entered into an agreement with Peel Hunt LLP for them independently to carry out on-market purchases of its 1p shares. The Programme will be conducted in compliance with Article 5(1)(b) of the UK version of Regulation (EU) No. 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 and the delegated regulations made pursuant to it.

Β 

Enquiries:

Craneware plc

+44 (0)131 550 3100

Keith Neilson, CEO

Craig Preston, CFO

Β 

Alma (Financial PR)

+44 (0)20 3405 0205

Caroline Forde, Joe Pederzolli, Kinvara Verdon

craneware@almapr.co.uk

Peel Hunt (NOMAD and Joint Broker)Β 

+44 (0)20 7418 8900

Dan Webster, Andrew Clark, Lait Bose

Investec Bank PLC (Joint Broker)

+44 (0)20 7597 5970

Patrick Robb, Henry Reast, Sebastian Lawrence

Berenberg (JointΒ Broker)

+44 (0)20 3207 7800

Mark Whitmore, Richard Andrews, Dan Gee-Summons

Β 

Β 

About Craneware

We at The Craneware Group of companies, including our latest additions Sentry Data Systems and Agilum Healthcare Intelligence, passionately believe we can impact healthcare profoundly by delivering the insights healthcare organisations need to also transform the business of healthcare. Our shared vision is to be the operational and financial partner for US healthcare providers.

Our combined suite of applications and industry-leading team of experts help our customers contextualise operational, financial, and clinical data, providing insights that clearly demonstrate what great looks like. These value cycle insights deliver revenue integrity and 340B compliance, as well as margin and operational intelligence - something no other single partner can provide.

Together, approximately 40% of registered US hospitals are now our customers, including more than 12,000 US hospitals, health systems and affiliated retail pharmacies and clinics. Our customers are operating with a financial impact of nearly half a trillion dollars. We have data sets from customers covering more than 165 million unique patients encounters.

Learn more atΒ www.thecranewaregroup.com

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
POSBRGDSDUBDGXB
Date   Source Headline
20th May 202511:27 amRNSForm 8.5 (EPT/NON-RI)-Craneware plc
20th May 202511:09 amRNSForm 8.5 (EPT/RI)-Craneware plc
20th May 20259:59 amRNSForm 8.5 (EPT/RI) - Craneware PLC
20th May 20259:29 amRNSForm 8.3 - Craneware PLC
19th May 20254:23 pmRNSForm 8.5 (EPT/NON-RI)-Craneware plc
19th May 20254:02 pmRNSForm 8.3 - Craneware plc
19th May 20253:20 pmRNSForm 8.3 - Craneware plc
19th May 20253:16 pmRNSForm 8.3 - CRANEWARE PLC
19th May 20252:29 pmGNWForm 8.3 - Craneware Plc
19th May 20252:08 pmBUSForm 8.3 - Craneware PLC
19th May 20251:45 pmGNWForm 8.3 - Craneware plc - Octopus Investments
19th May 20251:43 pmRNSForm 8.3 - Craneware Plc
19th May 20251:42 pmGNWForm 8.3 - [CRANEWARE PLC - 16 05 2025] - (CGAML)
19th May 20251:38 pmGNWForm 8.3 - [CRANEWARE PLC - 16 05 2025] - (CGWL)
19th May 202512:50 pmRNSForm 8.3 - Craneware PLC
19th May 202512:11 pmBUSForm 8.3 - Craneware plc
19th May 202512:00 pmRNSForm 8.5 (EPT/RI) Craneware Plc
19th May 202511:55 amRNSForm 8.3 - Craneware plc
19th May 202511:15 amRNSForm 8.5 (EPT/RI)-Craneware plc
19th May 202511:09 amRNSForm 8.5 (EPT/RI) - CRANEWARE PLC
19th May 202510:31 amRNSForm 8.5 (EPT/RI) - Craneware plc
19th May 20258:57 amGNWForm 8.5 (EPT/RI)-Craneware plc
16th May 20253:16 pmRNSResponse to Statement by Bain Capital
16th May 20251:16 pmRNSForm 8.3 - CRANEWARE PLC
16th May 20259:41 amRNSStatement re Possible Offer
1st May 20253:52 pmRNSHolding(s) in Company
28th Apr 20257:00 amRNSPurchase of Shares by Director and TVR
15th Apr 20257:00 amRNSBlock listing Interim Review
21st Mar 20251:50 pmRNSDividend Currency Election
11th Mar 20257:00 amRNSFY25 Interim Results
19th Feb 20253:23 pmRNSNotification of major holdings
13th Jan 20257:00 amRNSH1 FY25 Trading Update
29th Nov 20244:18 pmRNSDividend Currency Election
20th Nov 20241:57 pmRNSHolding(s) in Company
19th Nov 20245:13 pmRNSVesting of Long Term Incentive Plan Awards and TVR
13th Nov 20241:23 pmRNSResult of AGM
13th Nov 20247:00 amRNSAGM Statement and Board Changes
25th Oct 20243:02 pmRNSHolding(s) in Company
16th Oct 20245:05 pmRNSPosting of Annual Report and Notice of AGM
15th Oct 20247:00 amRNSBlock listing Interim Review
2nd Oct 202412:30 pmRNSTotal Voting Rights
23rd Sep 20245:31 pmRNSHolding(s) in Company
18th Sep 20247:00 amRNSExercise of Share Options
17th Sep 20244:40 pmRNSGrant of Long Term Incentive Plan Awards
12th Sep 20244:50 pmRNSNotification of Major Holdings
11th Sep 20243:45 pmRNSDirector/PDMR Dealings
10th Sep 20247:00 amRNSRelease and discharge of security in the Company
3rd Sep 20247:00 amRNSFY24 Final Results
27th Aug 20247:00 amRNSNotice of Results Presentations
18th Jul 20247:00 amRNSFY24 Trading Update and Notice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.